Business
Bionano Genomics Appoints Industry Leading Cytogeneticist Dr. Alka Chaubey as the Company’s First Chief Medical Officer to Help Lead the Conversion of Cytogenetics to Digital Cytogenetics with Saphyr
Dr. Chaubey is a key opinion leader in cytogenetics who has developed, validated and commercialized dozens of molecular and cytogenetic tests based on next
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Dr. Chaubey is a key opinion leader in cytogenetics who has developed, validated and commercialized dozens of molecular and cytogenetic tests based on next generation sequencing, microarray and COVID-19 RT-PCR, she has led the FDA clearance of diagnostic tests and led the efforts to obtain reimbursement for novel assays that are widely used. Her experience will guide Bionano towards its goal of widespread clinical adoption of Saphyr.\nSAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Dr. Alka Chaubey, PhD, FACMG, will join Bionano as its first Chief Medical Officer, effective August 31, 2020. Dr. Chaubey is well known throughout the molecular diagnostics and cytogenetics communities for her contributions to innovation directed toward improving patient outcomes by making the clinical testing process more efficient and more effective. Her breadth of experience includes developing and validating clinical tests, leading the process to obtain FDA clearance for whole-genome cytogenetic tests, engaging with third party payors to obtain reimbursement for novel assays, running clinical trials and leading CLIA-certified, CAP-accredited laboratories as their laboratory director. As Chief Medical Officer of Bionano, she will take the lead in driving toward our goal of global, widespread adoption of Saphyr for use in various clinical applications, including digital cytogenetics.\n Dr. Chaubey comes to Bionano with almost 20 years of scientific and clinical experience, including at PerkinElmer, where she currently serves as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis. She holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant Professor of Pathology of the Medical College of Georgia at Augusta University. Previously, Dr. Chaubey was Director of the Cytogenomics Laboratory of the Greenwood Genetic Center. Her breadth of clinical experience spans an array of clinical indications, including constitutional disorders, non-invasive prenatal Testing (NIPT) assay for common aneuploidies, the FDA Laboratory Developed Test (LDT-EUA) submissions for COVID-19 assays, a Bionano Saphyr-based test for Facioscapulohumeral...